Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers for Preferred Lantus Use in T2DM
NCT01500850Phase 4Unknown
- Sponsor
- ikfe CRO
- Start
- Oct 2011
- Primary completion
- Oct 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin glargine in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by ikfe CRO. Primary endpoint: Fasting Intact Proinsulin Secretion at 24 weeks. Status: unknown.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01500850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01500850.